Browse CA1

Summary
SymbolCA1
Namecarbonic anhydrase I
Aliases CA-I; HEL-S-11; carbonate dehydratase I; epididymis secretory protein Li 11; Carbonic anhydrase 1
Chromosomal Location8q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm.
Domain PF00194 Eukaryotic-type carbonic anhydrase
Function

Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.

> Gene Ontology
 
Biological Process GO:0006730 one-carbon metabolic process
GO:0006820 anion transport
GO:0015701 bicarbonate transport
GO:0015711 organic anion transport
Molecular Function GO:0004064 arylesterase activity
GO:0004089 carbonate dehydratase activity
GO:0016829 lyase activity
GO:0016835 carbon-oxygen lyase activity
GO:0016836 hydro-lyase activity
GO:0052689 carboxylic ester hydrolase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00910 Nitrogen metabolism
Reactome R-HSA-1237044: Erythrocytes take up carbon dioxide and release oxygen
R-HSA-1247673: Erythrocytes take up oxygen and release carbon dioxide
R-HSA-1430728: Metabolism
R-HSA-1480926: O2/CO2 exchange in erythrocytes
R-HSA-1475029: Reversible hydration of carbon dioxide
Summary
SymbolCA1
Namecarbonic anhydrase I
Aliases CA-I; HEL-S-11; carbonate dehydratase I; epididymis secretory protein Li 11; Carbonic anhydrase 1
Chromosomal Location8q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CA1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCA1
Namecarbonic anhydrase I
Aliases CA-I; HEL-S-11; carbonate dehydratase I; epididymis secretory protein Li 11; Carbonic anhydrase 1
Chromosomal Location8q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CA1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCA1
Namecarbonic anhydrase I
Aliases CA-I; HEL-S-11; carbonate dehydratase I; epididymis secretory protein Li 11; Carbonic anhydrase 1
Chromosomal Location8q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.7310.0448
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8950.423
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5250.711
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.670.434
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2340.876
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.8470.66
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8620.318
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.960.396
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0630.863
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.12.78.40.12
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.13.47.70.176
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117011.8-11.80.193
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCA1
Namecarbonic anhydrase I
Aliases CA-I; HEL-S-11; carbonate dehydratase I; epididymis secretory protein Li 11; Carbonic anhydrase 1
Chromosomal Location8q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CA1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCA1
Namecarbonic anhydrase I
Aliases CA-I; HEL-S-11; carbonate dehydratase I; epididymis secretory protein Li 11; Carbonic anhydrase 1
Chromosomal Location8q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CA1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CA1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCA1
Namecarbonic anhydrase I
Aliases CA-I; HEL-S-11; carbonate dehydratase I; epididymis secretory protein Li 11; Carbonic anhydrase 1
Chromosomal Location8q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CA1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCA1
Namecarbonic anhydrase I
Aliases CA-I; HEL-S-11; carbonate dehydratase I; epididymis secretory protein Li 11; Carbonic anhydrase 1
Chromosomal Location8q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CA1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCA1
Namecarbonic anhydrase I
Aliases CA-I; HEL-S-11; carbonate dehydratase I; epididymis secretory protein Li 11; Carbonic anhydrase 1
Chromosomal Location8q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CA1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCA1
Namecarbonic anhydrase I
Aliases CA-I; HEL-S-11; carbonate dehydratase I; epididymis secretory protein Li 11; Carbonic anhydrase 1
Chromosomal Location8q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CA1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CA1.
ID Name Drug Type Targets #Targets
DB00232MethyclothiazideSmall MoleculeCA1, CA2, CA4, SLC12A14
DB00273TopiramateSmall MoleculeCA1, CA2, CA3, CA4, GABRA1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5 ......23
DB00311EthoxzolamideSmall MoleculeCA1, CA2, CA3, CA4, CA75
DB00381AmlodipineSmall MoleculeCA1, CACNA1B, CACNA1C, CACNA1D, CACNA1S, CACNA2D1, CACNA2D3, CACNB ......9
DB00423MethocarbamolSmall MoleculeCA11
DB00436BendroflumethiazideSmall MoleculeCA1, CA2, CA4, KCNMA1, SLC12A35
DB00562BenzthiazideSmall MoleculeCA1, CA12, CA2, CA4, CA9, SLC12A36
DB00606CyclothiazideSmall MoleculeCA1, CA2, CA4, FXYD2, SFRP45
DB00703MethazolamideSmall MoleculeCA1, CA2, CA3, CA4, CA75
DB00774HydroflumethiazideSmall MoleculeATP1A1, CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A18
DB00819AcetazolamideSmall MoleculeAQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA78
DB00869DorzolamideSmall MoleculeCA1, CA2, CA3, CA44
DB00880ChlorothiazideSmall MoleculeCA1, CA2, CA4, SLC12A34
DB00909ZonisamideSmall MoleculeCA1, CA10, CA11, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, ......31
DB00999HydrochlorothiazideSmall MoleculeCA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A37
DB01021TrichlormethiazideSmall MoleculeATP1A1, CA1, CA2, CA4, SLC12A15
DB01031EthinamateSmall MoleculeCA1, CA22
DB01119DiazoxideSmall MoleculeATP1A1, CA1, CA2, KCNJ11, KCNMA1, SLC12A36
DB01144DiclofenamideSmall MoleculeCA1, CA2, CA3, CA4, CA75
DB01194BrinzolamideSmall MoleculeCA1, CA2, CA3, CA4, CA5A5
DB01325QuinethazoneSmall MoleculeCA1, CA2, SLC12A1, SLC12A2, SLC12A35
DB08155N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDESmall MoleculeCA1, CA22
DB081563-[4-(AMINOSULFONYL)PHENYL]PROPANOIC ACIDSmall MoleculeCA1, CA22
DB08157ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATESmall MoleculeCA1, CA22
DB08846Ellagic AcidSmall MoleculeCA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1 ......17
DB09460Sodium carbonateSmall MoleculeCA1, CA2, CA4, CA94
DB09472Sodium sulfateSmall MoleculeCA1, CA22